Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $123, Implies 24% Upside

What happened

Spyre Therapeutics’ average 12-month share-price target rose from $122.33 to $123, based on estimates from 15 analysts. The new target implies approximately 24% potential upside from the Nov. 3 closing price, while the consensus rating remains Buy among 17 covering analysts.

Confirmed

Global impact / market context

A higher analyst target can influence investor expectations, but it is a forecast, not a promised return. If investors respond to the implied upside by buying shares, demand could increase; the article reports no change in Spyre’s revenue, costs, or cash available.

Analyst inference

The report presents a broadly positive analyst view: 16 of 17 covering analysts rate the stock Buy, one rates it Hold, and none rates it Sell. Targets range from $110 to $135, indicating analysts differ on the potential share value.

Confirmed

What to watch

1. Watch whether Spyre’s share price moves toward or away from $123; this is an analyst estimate, and the article does not report an actual price change. Analyst inference
2. Compare future analyst targets and ratings with the current figures: the average target is $123, based on 15 estimates, while 17 analysts provide the consensus rating. Confirmed
3. Look for company updates that could explain analysts’ forecasts, especially developments affecting sales, spending, or cash available; none are described in this report. Analyst inference

Evidence

• Original source link unavailable